KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $63.3 million.

  • Rigel Pharmaceuticals' Total Current Liabilities rose 73.81% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 73.81%. This contributed to the annual value of $63.3 million for FY2024, which is 18.83% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Total Current Liabilities stood at $63.3 million, which was up 18.83% from $53.3 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Total Current Liabilities registered a high of $65.2 million during FY2022, and its lowest value of $40.8 million during FY2020.
  • Its 3-year average for Total Current Liabilities is $60.6 million, with a median of $63.3 million in 2024.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Total Current Liabilities decreased by 29.84% in 2020, and later surged by 55.61% in 2021.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Total Current Liabilities stood at $40.8 million in 2020, then soared by 55.61% to $63.6 million in 2021, then grew by 2.61% to $65.2 million in 2022, then fell by 18.32% to $53.3 million in 2023, then rose by 18.83% to $63.3 million in 2024.